Fragment 176-191 / CJC-1295 / Ipamorelin Blend
Also known as: Fragment 176-191 & CJC-1295 & Ipamorelin, Fragment, CJC-1295, Ipamorelin, Fragment, Modified GRF, Ipamorelin
A three-part research blend combining the lipolytic HGH Fragment 176-191 with the GHRH analog CJC-1295 (No DAC) and the selective ghrelin-receptor agonist Ipamorelin. It is studied for its combined effect on endogenous growth hormone release and fat metabolism.
Last updated
Mechanism of Action
CJC-1295 (No DAC), a modified GRF 1-29 analog, binds the pituitary GHRH receptor to amplify the amplitude of growth hormone pulses, while Ipamorelin selectively activates the GHS-R1a (ghrelin) receptor to trigger a discrete GH pulse without significantly raising cortisol or prolactin. The two secretagogues act through complementary, synergistic pathways to increase pulsatile GH and downstream IGF-1. HGH Fragment 176-191 is the C-terminal lipolytic domain of growth hormone and is thought to stimulate beta-3 adrenergic lipolysis and inhibit lipogenesis without the glucose-altering or IGF-1-mediated effects of full-length GH.
- Half-life
- Mixed: Ipamorelin ~2 hours, CJC-1295 (No DAC) ~30 minutes, HGH Fragment 176-191 ~20-30 minutes
- Administration Routes
- subcutaneous
- Research Status
- Research Chemical
Reported Benefits
- Studied for increased pulsatile growth hormone release
- Investigated for adipose tissue lipolysis and fat loss
- Examined for improved body composition in research models
- Researched for enhanced recovery and lean tissue support
- Studied for sleep quality and slow-wave sleep effects
- Investigated for IGF-1 elevation without exogenous GH
Potential Side Effects
- Injection-site redness, itching, or transient swelling
- Water retention and tingling or numbness in extremities
- Transient flushing or lightheadedness after injection
- Increased appetite from ghrelin-receptor activity
- Headache or fatigue
Common Dosing
In the research literature, combined blends are studied at roughly 100-300 mcg of each secretagogue component per administration, 1-2 times daily, often pre-sleep or fasted. For research-use only; not personal medical advice.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Active or history of malignancy
- Pregnancy or breastfeeding
- Known hypersensitivity to any component peptide
CJC-1295 (No DAC) / Ipamorelin / GHRP-2 Blend
This three-peptide blend pairs CJC-1295 without DAC (a GHRH analog) with two ghrelin-mimetic secretagogues, Ipamorelin and GHRP-2, to maximize a clean, synergistic growth hormone pulse. All components are unapproved research peptides.
HGH Fragment 176-191
HGH Fragment 176-191 is the C-terminal fragment of human growth hormone studied primarily for its fat-reducing effects without the broader growth-promoting actions of full-length GH. It is a popular research compound for lipolysis.
Sermorelin / Ipamorelin Blend
A widely studied research blend combining the GHRH analog Sermorelin with the highly selective ghrelin-receptor agonist Ipamorelin. It is examined for clean, synergistic growth hormone release with minimal off-target effects.
- View
The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice
2001
- View
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
2006
- View
Ipamorelin, the first selective growth hormone secretagogue
1998